NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01592370: Phase 1/2: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Sponsor
Bristol-Myers Squibb
Collaborator
Janssen, LP
ClinicalTrials.gov Identifier: NCT01592370
Official Title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
First Posted : May 7, 2012
Click here for details on ClinicalTrials.gov
Nivolumab (Code C68814)
BMS-936558
CMAB819
MDX-1106
NIVO
Nivolumab
NIVOLUMAB
Nivolumab Biosimilar CMAB819
ONO-4538
Opdivo
Ipilimumab (Code C2654)
Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
BMS-734016
Ipilimumab
IPILIMUMAB
ipilimumab
Ipilimumab Biosimilar CS1002
MDX-010
MDX-CTLA4
Yervoy
Lirilumab (Code C103820)
BMS-986015
IPH2102
Lirilumab
LIRILUMAB
anti-KIR monoclonal antibody IPH2102
Daratumumab (Code C74007)
Anti-CD38 Monoclonal Antibody
Daratumumab
DARATUMUMAB
Darzalex
HuMax-CD38
JNJ-54767414
Biological: Nivolumab
Biological: Ipilimumab
Biological: Lirilumab
Biological: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone
J Clin Oncol; 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Location
United States, California
United States, Colorado
United States, Connecticut
United States, Florida
United States, Indiana
United States, Kansas
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Nebraska
United States, New Jersey
United States, New York
United States, Ohio
United States, Oregon
United States, Pennsylvania
United States, Utah
Europe
Belgium
France
Greece
Italy
Poland